Evidence map›Paper›PMID 34827309›Full record

ArticleAntibiotics (Basel, Switzerland)2021

Repurposing Eltrombopag for Multidrug Resistant

Hyunjung Lee, Jaehoan Lee, Juchan Hwang, Sinyoung Park, Namyoul Kim, Kideok Kim, Honggun Lee, David Shum, Soojin Jang

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Drug Repurposing: An Emerging Strategy inJournal of microbiology and biotechnology · 2025
    Review
  3. Article
  4. Article
  5. Antimicrobial and Antibiofilm Effects of Bithionol againstAntibiotics (Basel, Switzerland) · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hyunjung LeeAntimicrobial Resistance Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Jaehoan LeeAntimicrobial Resistance Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Juchan HwangAntimicrobial Resistance Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.ORCID 0000-0002-3207-6769
Sinyoung ParkAnimal Facility Team, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Namyoul KimScreening Discovery Platform, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Kideok KimScreening Discovery Platform, Institut Pasteur Korea, Seongnam-si 13488, Korea.ORCID 0000-0002-3706-8821
Honggun LeeScreening Discovery Platform, Institut Pasteur Korea, Seongnam-si 13488, Korea.
David ShumScreening Discovery Platform, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Soojin JangAntimicrobial Resistance Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Institut Pasteur Korea · KR

Funding

National Research Foundation of Korea NRF-2017M3A9G6068246National Research Foundation of Korea NRF-2019M3E5D5064653
6 · The paper itself

Abstract

The continuous rise of antimicrobial resistance urgently demands new therapeutic agents for human health. Drug repurposing is an attractive strategy that could significantly save time delivering new antibiotics to clinics. We screened 182 US Food and Drug Administration (FDA)-approved drugs to identify potential antibiotic candidates against

Indexed as

drug repurposingeltrombopagin vivo efficacyMRSAStaphylococcus aureus

Identifiers

PMID34827309
PMCPMC8615030
OpenAlexW3211774631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.